Phase I Trial of 225Ac-J591 in Patients With mCRPC
Status:
Active, not recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-center Phase I dose escalation study designed to determine the
dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of 225Ac-J591 in a single
dose regimen.
Phase:
Phase 1
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH) Prostate Cancer Foundation United States Department of Defense